CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02259114
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:51.006642+00:00
- Published At
- 2018-10-01T00:00:00+00:00
- Record Updated At
- 2021-01-26
- Results Posted At
- 2018-10-01
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["NUT Midline Carcinoma", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation", "Castrate-resistant Prostate Cancer", "CRPC", "Pancreatic Ductal Adenocarcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-01-26"- protocolSection.identificationModule.nctId
"NCT02259114"- protocolSection.identificationModule.officialTitle
"A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-10-01"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.